Effect of amoxicillin on the gut microbiome of children with severe acute malnutrition in Madarounfa, Niger: a retrospective metagenomic analysis of a placebo-controlled trialOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study examined how a 7-day course of amoxicillin affects the gut microbiome and antibiotic resistome of children treated for severe acute malnutrition. It was a secondary, retrospective metagenomic analysis nested within a randomised, double-blinded, placebo-controlled trial (NCT01613547). Faecal samples were collected at baseline and multiple follow-up points (weeks 1, 4, 8, and 12, with a subset followed out to week 104) and profiled by metagenomic sequencing. The design let researchers track both immediate and longer-term shifts in gut microbial composition and resistance genes.
Who was studied?
The source trial enrolled children aged 6 to 59 months with severe acute malnutrition treated as outpatients in Madarounfa, Niger, out of an overall cohort of 2,399 children. For this analysis, 161 children were randomly selected for initial 12-week follow-up (September 23, 2013 to February 3, 2014), and a convenience sample from that group, chosen by anthropometric measures, was followed again two years later (September 28 to October 27, 2015). Reference controls consisted of 38 children without severe acute malnutrition and six children with severe acute malnutrition matched to the original cohort's baseline ages.
What were the most important findings?
The abstract text provided is truncated after stating that amoxicillin led to an immediate effect in the 12-week follow-up group, so the specific findings on the direction and magnitude of microbiome and resistome changes are not available here. What can be confirmed is that the study was designed to detect both acute (short-term) and long-term (two-year) changes in gut microbial communities and antibiotic resistance genes following amoxicillin treatment. No details on Faecalibacterium prausnitzii, butyrate, or specific anti-inflammatory commensals are present in the available abstract text.
What are the greatest implications of this study?
By pairing microbiome profiling with resistome surveillance in a placebo-controlled trial, this study offers a rare opportunity to weigh the benefits of antibiotic treatment for severe acute malnutrition against its effects on gut ecology and antibiotic resistance. The two-year follow-up component is notable because it allows assessment of whether short-course amoxicillin produces lasting, rather than only transient, changes to the microbiome and resistome. Findings from this kind of analysis could inform how clinicians weigh antibiotic use in vulnerable, malnourished pediatric populations against the risk of promoting antibiotic resistance.